RNA based Therapeutics And Vaccines Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017-2021 and Forecast 2022-2028

$ PRICE - $ 3,000.00$ 8,900.00

RNA based Therapeutics And Vaccines Market: By Type (RNA-Based Therapeutics and RNA-Based Vaccines), By Application (Genetic Disorders and Auto immune disorders), By End User (Diagnostic Centers, Hospitals, Academic & Research Institutes, Forensic Science Laboratories, and CROs (Contract Research Organizations)),and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

RNA based Therapeutics and Vaccines Market size was valued at USD 61,296.3 million in 2021 and is expanded to grow at a significant CAGR of 3.8% over 2022-2028. Global RNA based therapeutics and vaccines market is likely to experience a steep rise in its growth during the forecast period due to the rise in prevalence of chronic diseases such as diabetes, tuberculosis, cancer, and certain other cardiovascular conditions. RNA therapeutics and vaccines hold the distinction of providing better stability as compared to their counterparts. Though majority of them are under trials (as mentioned above), they are being increasingly preferred when it comes to treat obstinate disorders. Rapid advancement in technologies particularly in the healthcare sector has significantly lifted the demand for RNA based therapeutics and vaccines.  Healthcare sector have been bringing their minds together to bring stability to the RNA molecules in the body with limited bioavailability. It is the RNA therapeutics which when combined with protein/ lipid nanoparticles provide better stability. In spite of being in a clinical research phase the RNA therapeutics has been extensively explored with a primary aim to treat difficult diseases. One of the major factors which is driving the market is the rise of promising technologies such as antisense technology, smart technology, and RNAi interference technology. The RNA based therapeutics and vaccine market primarily find cures for cancer and infectious diseases and since the pool of patients is large, the demand for the market subsequently is also high. This creates a huge opportunity globally for RNA based Therapeutics and Vaccines market. The lack of alternative treatment options for rare diseases further boosted the growth of RNA-based therapeutics and vaccines during the forecast period. Aiding the growth of this market, increasing focus of legislative bodies on developing reimbursement policies has fueled the development process RNA’s molecules.

Recent Market Developments:

In Jan 2022, Novartis and Alnylam have agreed to collaborate on discovery and development of siRNA-based targeted therapy to restore functional liver cells in patients with end-stage liver disease. Agreement will bring Alnylam’s proprietary siRNA technology to bear on liver target identified by Novartis researchers.

In April 2020, Blackstone and Alnylam Entered Into $2 Billion Strategic Financing Collaboration to Accelerate the Advancement of RNAi Therapeutics

RNA based Therapeutics and Vaccines Market

MARKET SUMMARY
-
3.8%
  • Study Period– 2022-2028
  • Base Year– 2021
  • CAGR– 3.8%
  • Largest Market– North America
  • Fastest Growing Market– Europe

RNA based Therapeutics and Vaccines Market

  • The report on global RNA based Therapeutics and Vaccines Market gives historical, current, and future market sizes (US$ Mn) on the basis of product type, application, end user and geography.
  • RNA based Therapeutics and Vaccines Market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa
Key Players
  • Dicerna Pharmaceuticals, Inc.
  • Marina Biotech, Inc.
  • miRagen Therapeutics, Inc.
  • Quark Pharmaceuticals, Inc.
  • Regulus Therapeutics, Inc.
RNA based Therapeutics and Vaccines Market Dynamics

Gene silencing potential of RNA based therapeutics is the primary driver for the growth of this market. The other drivers include target specificity and selectivity of RNA therapeutics, more intense product focus versus platform technologies and virtual drug development models that enable companies to reduce the research cost. Factors such as expensive research, high failure rated accompanied with problems faced in drug delivery are anticipated to bring down the RNA based therapeutics and vaccines market.


North America Got Significant Share

RNA based Therapeutics and Vaccines Market

North America holds the major share in the RNA based therapeutics and vaccines market due to fast adoption to technologies and rise in prevalence of chronic diseases. Other factors which are driving the RNA based therapeutics and vaccines market is the extensive research done in order to commercialize the therapeutics. Hefty investment done for research and advancement in RNA based technologies coupled with support provided by various government of this region is helping the market in the region to grow at a steady rate. However, it has been noticed that business dynamics present in Asia Pacific is expected to provide lucrative opportunity to leading players of this RNA based therapeutics and vaccines market owing to the less cost required for clinical research in comparison to North America and Europe.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market and forecast 2022-28
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
RNA based Therapeutics and Vaccines Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The RNA-based therapeutics and vaccines market is projected to expand at a CAGR of 3.8% during the forecast period

Arrowhead Pharmaceuticals, Inc., BioNTech AG, CureVac AG, Dicerna Pharmaceuticals, Inc., Marina Biotech, Inc., miRagen Therapeutics, Inc.

North-America is the fastest-growing region for RNA-based therapeutics and vaccines market


Report

Table Of Content

Table of Content

  1. Executive Summary
  2. Global RNA based Therapeutics and Vaccines Market Introduction
    • Global RNA based Therapeutics and Vaccines Market – Taxonomy
    • Global RNA based Therapeutics and Vaccines Market –Definitions
      • By Product Type
      • By Application
  1. Global RNA based Therapeutics and Vaccines Market Dynamics
    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Global RNA based Therapeutics and Vaccines Market Dynamic Factors – Impact Analysis
    • Global RNA based Therapeutics and Vaccines Market – Competition Landscape
  2. Global RNA based Therapeutics and Vaccines Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025
    • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
    • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Market Opportunity Analysis
  3. Global RNA based Therapeutics and Vaccines Market, By Product Type, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
    • RNA based Therapeutics
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • RNA based Vaccines
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global RNA based Therapeutics and Vaccines Market, By Application, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
    • Oncology
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Immunology
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Infectious Diseases
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Rare Disease
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global RNA based Therapeutics and Vaccines Market Forecast, By Region, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
    • North America
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Europe
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Asia-Pacific
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Latin America
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Middle East and Africa
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Global RNA based Therapeutics and Vaccines Market – Opportunity Analysis Index, By Product Type, By Application, and Region, 2019 – 2025
  2. North America RNA based Therapeutics and Vaccines Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
    • Product Type Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • RNA based Therapeutics
      • RNA based Vaccines
    • Application Type Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Oncology
      • Immunology
      • Infectious Diseases
      • Rare Diseases
      • Others
    • Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • US
      • Canada
    • North America RNA based Therapeutics and Vaccines Market – By Product Type, Application Type, and Country, 2019 – 2025
    • North America RNA based Therapeutics and Vaccines Market Dynamics – Trends
  3. Europe Global RNA based Therapeutics and Vaccines Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
    • Product Type Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • RNA based Therapeutics
      • RNA based Vaccines
    • Application Type Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Oncology
      • Immunology
      • Infectious Diseases
      • Rare Diseases
      • Others
    • Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Russia
      • Poland
      • Rest of Europe
    • Europe RNA based Therapeutics and Vaccines Market – By Product Type, Application Type, and Country, 2019 – 2025
    • Europe RNA based Therapeutics and Vaccines Market Dynamics – Trends
  4. Asia Pacific RNA based Therapeutics and Vaccines Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
    • Product Type Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • RNA based Therapeutics
      • RNA based Vaccines
    • Application Type Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Oncology
      • Immunology
      • Infectious Diseases
      • Rare Diseases
      • Others
    • Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Japan
      • China
      • India
      • ASEAN
      • Australia & New Zealand
      • Rest of Asia Pacific
    • Asia RNA based Therapeutics and Vaccines Market – Opportunity Analysis Index, By Product Type, Application Type, and Country, 2019 – 2025
    • Asia RNA based Therapeutics and Vaccines Market Dynamics – Trends
  5. Latin America RNA based Therapeutics and Vaccines Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
    • Product Type Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • RNA based Therapeutics
      • RNA based Vaccines
    • Application Type Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Oncology
      • Immunology
      • Infectious Diseases
      • Rare Diseases
      • Others
    • Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Latin America RNA based Therapeutics and Vaccines Market – Opportunity Analysis Index, By Product Type, Application Type, and Country, 2019 – 2025
    • Latin America RNA based Therapeutics and Vaccines Market Dynamics – Trends
  6. Middle East and Africa RNA based Therapeutics and Vaccines Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
    • Product Type Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • RNA based Therapeutics
      • RNA based Vaccines
    • Application Type Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Oncology
      • Immunology
      • Infectious Diseases
      • Rare Diseases
      • Others
    • Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Gulf Cooperation Council (GCC) Countries
      • Israel
      • South Africa
      • Rest of MEA
    • MEA RNA based Therapeutics and Vaccines Market – Opportunity Analysis Index, By Product Type, Application Type, and Country, 2019 – 2025
    • MEA RNA based Therapeutics and Vaccines Market Dynamics – Trends
  7. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Product Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      • Moderna, Inc. (Massachusetts)
      • CureVac AG (Germany)
      • BioNTech AG (Germany)
      • Alnylam Pharmaceuticals, Inc. (Massachusetts)
      • Arbutus Biopharma Corporation (Canada)
      • miRagen Therapeutics, Inc. (Colorado)
      • Arrowhead Pharmaceuticals, Inc. (California)
      • Roche Holdings AG (Switzerland)
      • Sarepta Therapeutics, Inc. (Massachusetts)
      • Biogen (Massachusetts)
  1. Research Methodology
  2. Key Assumptions and Acronyms

Report

Company Profile

  • Alnylam Pharmaceuticals, Inc.
  • Arbutus Biopharma Corporation
  • Arrowhead Pharmaceuticals, Inc.
  • BioNTech AG
  • CureVac AG
  • Dicerna Pharmaceuticals, Inc.
  • Marina Biotech, Inc.
  • miRagen Therapeutics, Inc.
  • Moderna, Inc.
  • Quark Pharmaceuticals, Inc.
  • Regulus Therapeutics, Inc.
  • Sylentis S.A.

Description

RNA based Therapeutics and Vaccines Market size was valued at USD 61,296.3 million in 2021 and is expanded to grow at a significant CAGR of 3.8% over 2022-2028. Global RNA based therapeutics and vaccines market is likely to experience a steep rise in its growth during the forecast period due to the rise in prevalence of chronic diseases such as diabetes, tuberculosis, cancer, and certain other cardiovascular conditions. RNA therapeutics and vaccines hold the distinction of providing better stability as compared to their counterparts. Though majority of them are under trials (as mentioned above), they are being increasingly preferred when it comes to treat obstinate disorders. Rapid advancement in technologies particularly in the healthcare sector has significantly lifted the demand for RNA based therapeutics and vaccines.  Healthcare sector have been bringing their minds together to bring stability to the RNA molecules in the body with limited bioavailability. It is the RNA therapeutics which when combined with protein/ lipid nanoparticles provide better stability. In spite of being in a clinical research phase the RNA therapeutics has been extensively explored with a primary aim to treat difficult diseases. One of the major factors which is driving the market is the rise of promising technologies such as antisense technology, smart technology, and RNAi interference technology. The RNA based therapeutics and vaccine market primarily find cures for cancer and infectious diseases and since the pool of patients is large, the demand for the market subsequently is also high. This creates a huge opportunity globally for RNA based Therapeutics and Vaccines market. The lack of alternative treatment options for rare diseases further boosted the growth of RNA-based therapeutics and vaccines during the forecast period. Aiding the growth of this market, increasing focus of legislative bodies on developing reimbursement policies has fueled the development process RNA’s molecules.

Recent Market Developments:

In Jan 2022, Novartis and Alnylam have agreed to collaborate on discovery and development of siRNA-based targeted therapy to restore functional liver cells in patients with end-stage liver disease. Agreement will bring Alnylam’s proprietary siRNA technology to bear on liver target identified by Novartis researchers.

In April 2020, Blackstone and Alnylam Entered Into $2 Billion Strategic Financing Collaboration to Accelerate the Advancement of RNAi Therapeutics

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX